Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director · PRESIDENT, CEO | January 22, 2026 | January 26, 2026 |
| Zyla Life SciencesEGLT · Entity 148990 | Chief Medical Officer | June 08, 2017 | June 12, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,500 |
Reported balance
After 2026-01-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-24 · Exercise / conversion · Acquired 10,500 · Balance 10,500 |
| Common StockSEC Table I · non-derivative | Direct | 5,715 |
Reported balance
After 2026-01-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-01-24 · Tax withholding · Disposed 4,785 · Balance 5,715 F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 13,000 |
Reported balance
After 2026-01-25 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-01-25 · Exercise / conversion · Acquired 13,000 · Balance 13,000 |
| Common StockSEC Table I · non-derivative | Direct | 7,346 |
Reported balance
After 2026-01-25 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-01-25 · Tax withholding · Disposed 5,654 · Balance 7,346 F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $36.76 · Expires 2036-01-22 | Direct | 184,600 |
Reported balance
After 2026-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-22 · Grant · Acquired 184,600 · Balance 184,600 F2: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 52,900 |
Reported balance
After 2026-01-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-22 · Grant · Acquired 52,900 · Balance 52,900 F3: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 21,000 |
Reported balance
After 2026-01-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-24 · Exercise / conversion · Disposed 10,500 · Balance 21,000 F4: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 39,000 |
Reported balance
After 2026-01-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-25 · Exercise / conversion · Disposed 13,000 · Balance 39,000 F5: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.
F2: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F3: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
F4: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
F5: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
Zyla Life Sciences
Report date June 08, 2017 · Filed June 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2027-06-08 | Direct | 80,000 |
Reported balance
After 2017-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-08 · Grant · Acquired 80,000 · Balance 80,000 F1: 25% of the options will vest on the later of (i) the 6-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $3.33 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. 25% of the options will vest on the later of (i) the 12-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.05 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. The remaining 50% of the options will vest on the later of (i) the 24-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.76 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options will vest on the later of (i) the 6-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $3.33 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. 25% of the options will vest on the later of (i) the 12-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.05 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. The remaining 50% of the options will vest on the later of (i) the 24-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.76 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2021 Filed Aug 11, 2021 16:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 9,950 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-032526 · doc4.xml · derivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,469 Underlying: Common Stock · 9,950 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is currently vested with respect to 82,777 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 13, 2021. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 16:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 9,950 | $30.21 | $300,634.28 |
DisclosureSEC source: 0000899243-21-032526 · doc4.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.75. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 16:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 9,950 | $8.22 | $81,789.00 |
DisclosureSEC source: 0000899243-21-032526 · doc4.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 16:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 50 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-029687 · doc4.xml · derivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,419 Underlying: Common Stock · 50 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is currently vested with respect to 82,777 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 13, 2021. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 16:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 50 | $30.00 | $1,500.00 |
DisclosureSEC source: 0000899243-21-029687 · doc4.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 16:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 50 | $8.22 | $411.00 |
DisclosureSEC source: 0000899243-21-029687 · doc4.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 20:08 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 132,260 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023135 · doc4.xml · derivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,260 Underlying: Common Stock · 132,260 shares Expires 2030-08-18 F1 · derivative.exercise_date: The stock option shall vest in five equal annual installments beginning on August 21, 2021. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:40 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001179110-17-008926 · edgar.xml · derivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: 25% of the options will vest on the later of (i) the 6-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $3.33 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. 25% of the options will vest on the later of (i) the 12-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.05 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. The remaining 50% of the options will vest on the later of (i) the 24-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.76 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 17:05 UTC | Zyla Life Sciences EGLT · Entity 148990 | SaleCommon Stock | 536 | $5.16 | $2,765.76 |
DisclosureSEC source: 0001179110-17-005586 · edgar.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,212 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on August 6, 2014. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.11 to $5.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 16:59 UTC | Zyla Life Sciences EGLT · Entity 148990 | SaleCommon Stock | 536 | $7.75 | $4,154.00 |
DisclosureSEC source: 0001179110-17-000257 · edgar.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,748 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on August 6, 2014. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 16:28 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0001179110-16-032593 · edgar.xml · derivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2026-12-06 F1 · derivative.exercise_date: The option vests with respect to one-fourth of the underlying shares on the first anniversary of the grant date and with respect to one-forty eighth of the underlying shares each month thereafter until fully vested. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 17:22 UTC | Zyla Life Sciences EGLT · Entity 148990 | SaleCommon Stock | 536 | $7.69 | $4,121.84 |
DisclosureSEC source: 0001179110-16-030194 · edgar.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,284 F1 · kind: Sale effected pursuant to a Rule 10b5-1 trading plan to pay tax liability on vesting restricted stock. The restricted stock was originally granted on August 6, 2014. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.65 to $7.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.